StreetAlpha.app
Home › Stocks › ABSI

Absci Corp (ABSI)

Healthcare
$7.58
▲ +1.40%
LAST CLOSE · NOV 17

Absci uses artificial intelligence to design antibody drugs and is testing its lead candidate in clinical trials. It last closed at $7.58 on Nov 17, up 1.40% on the day. ABSI last reported earnings on Tue, Aug 11, 2026. The average 12-month price target from 7 analysts is $15.71 (+107.3% from the last close), with a high of $20.00 and a low of $14.00. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (7 buy, 0 hold, 0 sell).

AI Auto Pilots
Is ABSI in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$1.5M
−47.2% vs a year ago
Net income
−$125.7M
−8451.3% margin
EPS (diluted)
−$0.79
Free cash flow
−$112.6M
−7571.1% margin
Valuation
Market cap
$1.3B
172.7M shares
P/E
–
No P/E while losing money
Price to sales
880.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$13.4M
At Sep 30
Shareholder equity
$218.7M
Shares outstanding
172.7M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $4.0M$4.0MFY2021FY2022: $4.5M$4.5MFY2022FY2023: $5.7M$5.7MFY2023FY2024: $4.5M$4.5MFY2024FY2025: $2.8M$2.8MFY2025

From ABSI's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Aug 11
2026 · After the close (AMC)
Reported EPS
-$0.21
vs -$0.20 est. · miss
Year-ago EPS
—
Not on file
Options-implied move
±14.6%
Priced in before that report
Analyst consensus
Strong Buy
Based on 7 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
7firms
7 Buy0 Hold0 Sell
Each firm's latest rating on ABSI in the past 90 days
Average 12-month target
$15.71
▲ 107.3% upside

Based on 7 analysts who set a price target on ABSI in the past 90 days. The average target is $15.71, with a high of $20.00 and a low of $14.00, compared with the last close of $7.58.

$5$11$16$21PAST 13 TRADING DAYS12-MONTH TARGETSHIGH $20AVG $15.71LOW $14May 29LAST CLOSE+12 MO$5$11$16$21PAST 13 DAYSTARGETSHIGH $20AVG $15.71LOW $14May 29LAST CLOSE+12 MO
Highest target$20.00
Average target$15.71
Lowest target$14.00
Latest rating changes
GuggenheimTarget lowered
Nov 16Buy$15 → $14
NeedhamTarget raised
Nov 13Buy$11 → $15
JefferiesInitiated
Oct 29Buy$14
KeybancMaintained
Oct 16Buy$20
JP MorganMaintained
Oct 12Buy$15
DateFirmActionRatingPrice target
Nov 16GuggenheimTarget loweredBuy$15 → $14
Nov 13NeedhamTarget raisedBuy$11 → $15
Oct 29JefferiesInitiatedBuy$14
Oct 16KeybancMaintainedBuy$20
Oct 12JP MorganMaintainedBuy$15
Loading…

Technical Analysis

ABSI · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend, nearing oversold

The stock is 30% below its 20 day and 27% below its 50 day average. It is 9% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 38), near oversold. The nearest support is the Pivot at $7.56, and the nearest resistance the Pivot R1 at $7.77.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNear oversold
VolatilityHigh, 13.2%/day
Key levels
$12.5452 week high+65.4%
$9.8520 day average+29.9%
$9.6050 day average+26.6%
$9.40100 day average+24.0%
$8.17Swing high (Jun 15)+7.8%
$7.77Pivot R1+2.5%
$7.58Last close
$7.56Pivot−0.3%
$7.36Pivot S1−2.9%
$6.88200 day average−9.2%
$6.69Swing low (Jul 29)−11.7%
$2.2452 week low−70.4%
Indicators
RSI (14)38.48Weak, oversold below 30Neutral
MACD-0.37Below its signal lineBearish
Stochastic4.0Near the bottom of its rangeOversold
ADX (14)15.4No clear trend
Williams %R-94.5Oversold below −80, overbought above −20Oversold
CCI (20)-187.7Oversold below −100, overbought above 100Oversold
Rate of change−24.2%Change over 10 sessionsBearish
ATR (14)$1.00Typical daily range, 13.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for ABSI

What happened before

See how ABSI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ABSI usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ABSI has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ABSI in the last 90 days.

Loading…

See today’s whale options flow across the market →

ABSI Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲138 buying vs 81 selling
  • ▲Held by funds +0.8 pts
  • ▲Funds holding +22
  • ▲Superinvestors: 3 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding220198+11.1%
In funds' top 10330.0%
Held by funds88.6%87.8%+0.8 pts
New / increased56 / 8251 / 73+11.3%
Reduced / sold out47 / 3449 / 18+20.9%
Put/call ratio0.80––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ABSI institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ABSI is in one of them and how their past ABSI trades turned out.

ABSI in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ABSI in an article yet. Here's the latest on the wider market.

About Absci

Absci is a biopharmaceutical company based in Vancouver, Washington. It uses artificial intelligence to design antibody therapeutics aimed at biological targets that have received little prior research. Its lead candidate, ABS-201, is in clinical trials for hair loss and is planned for testing in endometriosis. The company also creates drug candidates with pharmaceutical partners for their own pipelines.

Headquarters
Vancouver, WA